Developing monoclonal antibody therapies for measles could lead to adverse pathogen evolution
Abstract
Monoclonal antibody therapies are being developed to treat measles in response to its recent resurgence. These therapies risk driving measles virus evolution in ways that might undermine the protection offered by vaccination, outweighing potential benefits.
Fields of Study & Subjects
Virology and Viral Diseases
Evolution and Genetic Dynamics
SARS-CoV-2 and COVID-19 Research
Publication details
- Journal / source
- PLoS Biology
- Volume
- 24
- Issue
- 3
- Pages
- e3003701–e3003701
- Publication date
- 3 March 2026
- Language
- EN